Unichem Labs receives US regulatory nod for generic version of Buspar tablets

Unichem Labs' Buspirone Hydrochloride tablets are a generic version of Bristol-Myers Squibb Company's Buspar tablets in the same strengths.

New Delhi: Drug firm Unichem Laboratories on Friday said it has received approval from the US health regulator to market its generic Buspirone Hydrochloride tablets used for management of anxiety disorders.

The company has received abbreviated new drug application (ANDA) approval from the United States Food and Drug Administration (USFDA) to market its Buspirone Hydrochloride tablets USP, in the strengths of 5 mg, 10 mg, 15 mg, and 30 mg, Unichem Laboratories said in a BSE filing.

Also Read: Unichem Labs wins USFDA nod for pain management drug Tramadol Hydrochloride tablets

The company's tablets are a generic version of Bristol-Myers Squibb Company's Buspar tablets in the same strengths, it added.

The product will be commercialised from the company's Ghaziabad plant, Unichem said.

Buspirone Hydrochloride tablets are indicated for the management of anxiety disorders or the short-term relief of the symptoms of anxiety, it added.

Also Read: Unichem Labs gets tentative USFDA nod for generic version of JnJ Zyrtec-D 12 Hour